


Supplementary Table 5. SUCRA for targets on the effects of various outcomes.

Note: ACC, acetyl-coenzyme A carboxylase; FGF, fibroblast growth factor; FXR, farnesoid X receptor; GLP-1, glucagon-like peptide-1; GCG, glucagon; GIP, glucose-dependent insulintropic polypeptide; PPAR, peroxisome proliferator-activated receptor; THR, thyroid hormone receptor; RA, receptor agonist; SUCRA, surface under the cumulative ranking curve analysis.


Supplementary Table 5.1. Fibrosis improvement ≥ 1 stage without steatohepatitis worsening

Treatment	SUCRA	PrBest	Mean Rank
d-(R)-Pioglitazone	79.3	48.3	2.9
FGF21 analogue	71.9	14	3.5
GLP-1/GCG dual RA	69.5	16.1	3.7
PPAR agonist	61.3	5.9	4.5
GLP-1/GIP dual RA	59.7	10.8	4.6
FXR agonist	55.5	2.1	5
FGF19 analogue	39.8	2.8	6.4
THR- β agonist	32.4	0	7.1
GLP-1 RA	30.1	0	7.3
Placebo	0.5	0	10




Supplementary Table 5.2. Steatohepatitis improvement without fibrosis worsening

Treatment	SUCRA	PrBest	Mean Rank
GLP-1/GIP dual RA	91.7	58.1	1.7
GLP-1/GCG dual RA	86.5	33.4	2.2
GLP-1 RA	63.5	2.2	4.3
FGF21 analogue	56.9	2.3	4.9
FGF19 analogue	52.6	3.1	5.3
THR- β agonist	48.8	0.3	5.6
PPAR agonist	43.8	0.3	6.1
FXR agonist	33.9	0.1	6.9
d-(R)-Pioglitazone	17.9	0.2	8.4
Placebo	4.3	0	9.6




Supplementary Table 5.3. Relative change from baseline in liver fat content

Treatment	SUCRA	PrBest	Mean Rank
GLP-1/GIP/GCG triple RA	97.5	83.5	1.3
FGF21 analogue	85.00	6.10	2.7
GLP-1/GCG dual RA	83.80	6.10	2.8
GLP-1/GIP dual RA	65.90	4.10	4.8
ACC inhibitor	57.70	0.20	5.7
FGF19 analogue	47.70	0.00	6.8
THR- β agonist	44.90	0.00	7.1
PPAR agonist	37.4	0	7.9
GLP-1 RA	30.20	0.00	8.7
FXR agonist	25.70	0.00	9.2
d-(R)-Pioglitazone	23.50	0.00	9.4
Placebo	0.80	0.00	11.9




Supplementary Table 5.4. Absolute change from baseline in liver fat content

Treatment	SUCRA	PrBest	Mean Rank
GLP-1/GCG dual RA	94.3	71.3	1.6
FGF21 analogue	79.7	6.7	3.2
FGF19 analogue	58	1	5.6
GLP-1 RA+ACC inhibitor	57.5	4.5	5.7
GLP-1 RA+ACC inhibitor+FXR agonist	56.9	4.3	5.7
GLP-1 RA+FXR agonist	48.5	2.8	6.7
THR- β agonist	46.9	0.7	6.8
PPAR agonist	44.6	8.1	7.1
FXR agonist	38.1	0.1	7.8
d-(R)-Pioglitazone	36.6	0.5	8
GLP-1RA	30.9	0	8.6
Placebo	8.1	0	11.1




Supplementary Table 5.5. Alanine aminotransferase (ALT)

Treatment	SUCRA	PrBest	Mean Rank
GLP-1 RA+ACC inhibitor+FXR agonist	91.7	50.5	1.9
GLP-1 RA+ACC inhibitor	87.1	28	2.4
GLP-1 RA+FXR agonist	77.3	9.1	3.5
PPAR agonist	66.7	3.4	4.7
FGF19 analogue	65.5	3.7	4.8
THR- β Agonist	55	5.3	6
FGF21 analogue	49.6	0	6.5
GLP-1 RA	37.5	0	7.9
GLP-1/GCG dual RA	35.3	0	8.1
FXR agonist	20.9	0	9.7
d-(R)-Pioglitazone	12	0	10.7
Placebo	1.6	0	11.8




Supplementary Table 5.6. Aspartate aminotransferase (AST)

Treatment	SUCRA	PrBest	Mean Rank
GLP-1 RA+ACC inhibitor	89	40.9	2.2
GLP-1 RA+ACC inhibitor+FXR agonist	87.4	35.8	2.4
GLP-1 RA+FXR agonist	76.1	11.8	3.6
GLP-1/GCG dual RA	70.7	6.1	4.2
FGF19 analogue	60	3.4	5.4
GLP-1 RA	50.2	0.1	6.5
FGF21 analogue	49	0.4	6.6
THR- β agonist	37.7	0.9	7.9
PPAR agonist	37.4	0.3	7.9
FXR agonist	19.1	0	9.9
d-(R)-Pioglitazone	18.8	0.3	9.9
Placebo	4.6	0	11.5




Supplementary Table 5.7. Body weight

Treatment	SUCRA	PrBest	Mean Rank
GLP-1/GCG dual RA	99.4	93.9	1.1
GLP-1 RA+FXR agonist	89.9	5.8	2.1
GLP-1 RA+ACC inhibitor	75.7	0.3	3.7
GLP-1 RA+ACC inhibitor+FXR agonist	70.9	0	4.2
GLP-1 RA	69.1	0	4.4
FXR agonist	48.7	0	6.6
PPAR agonist	38.1	0	7.8
FGF19 analogue	37.7	0	7.9
FGF21 analogue	31.4	0	8.5
THR- β agonist	17.6	0	10.1
Placebo	13	0	10.6
d-(R)-pioglitazone	8.5	0	11.1




Supplementary Table 5.8. Triglyceride

Treatment	SUCRA	PrBest	Mean Rank
PPAR agonist	86.2	33.2	2.2
GLP-1/GCG dual RA	79.4	23.6	2.9
GLP-1 RA+FXR agonist	76.8	35	3.1
FGF21 analogue	65.6	4.2	4.1
GLP-1 RA	61.3	3.1	4.5
FGF19 analogue	57.3	0.8	4.8
Placebo	24.7	0	7.8
GLP-1 RA+ACC inhibitor	19.5	0.1	8.2
FXR agonist	17.5	0	8.4
GLP-1 RA+ACC inhibitor+FXR agonist	11.7	0	9




Supplementary Table 5.9. Low density lipoprotein-cholesterol (LDL-C)

Treatment	SUCRA	PrBest	Mean Rank
GLP-1 RA	78.7	23.1	2.9
GLP-1RA+ACC Inhibitor	69.7	22.2	3.7
FGF21 analogue	67.6	18.1	3.9
GLP-1/GCG dual RA	61.1	14.2	4.5
GLP-1 RA+FXR agonist	60.6	15.4	4.5
GLP-1 RA+FXR agonist+ACC inhibitor	49.5	6.2	5.5
Placebo	42.7	0	6.2
PPAR agonist	29.3	0.5	7.4
FXR agonist	27.4	0.3	7.5
FGF19 analogue	13.4	0	8.8




Supplementary Table 5.10. High density lipoprotein-cholesterol (HDL-C)

Treatment	SUCRA	PrBest	Mean Rank
FGF21 analogue	94.5	73.8	1.5
PPAR agonist	76.1	9.1	3.2
GLP-1 RA	58.2	2.2	4.8
GLP-1/GCG dual RA	56.1	2.8	5
FGF19 analogue	51.2	0.9	5.4
GLP-1 RA+FXR agonist	50.4	8.2	5.5
Placebo	37.6	0	6.6
GLP-1 RA+ACC inhibitor	25.9	0.7	7.7
GLP-1 RA+ACC inhibitor+FXR agonist	25.9	2.2	7.7
FXR agonist	24.2	0.1	7.8




Supplementary Table 5.11. Total cholesterol

Treatment	SUCRA	PrBest	Mean Rank
FGF21 analogue	86.4	53.9	2.2
GLP-1 RA	73.7	11.2	3.4
GLP-1/GCG dual RA	67.8	9.6	3.9
GLP-1 RA+FXR agonist	62.6	12.9	4.4
GLP-1 RA+ACC inhibitor	58.4	9.6	4.7
GLP-1 RA+ACC inhibitor+FXR agonist	42.3	2.7	6.2
Placebo	40.8	0	6.3
PPAR agonist	32.6	0.1	7.1
FGF19 analogue	22.6	0	8
FXR agonist	12.7	0	8.9




Supplementary Table 5.12. Glycated hemoglobin (HbA1c)

Treatment	SUCRA	PrBest	Mean Rank
GLP-1 RA+ACC inhibitor	77.5	29.5	3.5
GLP-1 RA+FXR agonist	69.3	16.9	4.4
GLP-1/GCG dual RA	67.8	13.2	4.5
GLP-1 RA	64.2	4.8	4.9
GLP-1 RA+ACC inhibitor+FXR agonist	62.9	11.6	5.1
d-(R)-Pioglitazone	56.2	10.3	5.8
ACC inhibitor	53.9	8.8	6.1
PPAR agonist	50.5	2	6.4
FGF21 analogue	44.9	2.8	7.1
FGF19 analogue	20.3	0.1	9.8
FXR agonist	17.7	0	10.1
Placebo	14.8	0	10.4




Supplementary Table 5.13. Fasting blood glucose

Treatment	SUCRA	PrBest	Mean Rank
GLP-1 RA+ACC inhibitor	84.1	30	2.4
GLP-1 RA	82.3	16.7	2.6
PPAR agonist	75.7	21	3.2
FGF21 analogue	66	27.9	4.1
GLP-1 RA+ACC inhibitor+FXR agonist	56.6	1.1	4.9
GLP-1 RA+FXR agonist	54.2	0.7	5.1
GLP-1/GCG dual RA	28.9	2.6	7.4
Placebo	25.5	0	7.7
FXR agonist	14.1	0	8.7
FGF19 analogue	12.5	0	8.9




Supplementary Table 5.14. Enhanced liver fibrosis (ELF) score

Treatment	SUCRA	PrBest	Mean Rank
GLP-1/GIP dual RA	87.50	52.50	2.4
FGF21 analogue	76.00	12.90	3.6
GLP-1 RA+ACC inhibitor	63.80	17.00	5
GLP-1 RA	61.70	3.30	5.2
GLP-1 RA+FXR agonist	49.20	5.40	6.6
GLP-1/GCG dual RA	46.30	2.50	6.9
FGF19 analogue	46.10	0.30	6.9
d-(R)-Pioglitazone	46.10	2.40	6.9
PPAR agonist	43.10	0.50	7.3
GLP-1 RA+ACC inhibitor+FXR agonist	42.6	3.2	7.3
FXR agonist	29.30	0.00	8.8
Placebo	8.30	0.00	11.1



Supplementary Table 5.15. N-terminal type III collagen propeptide (PRO-C3)

Treatment	SUCRA	PrBest	Mean Rank
GLP-1/GIP dual RA	100	100	1
GLP-1 RA	72.7	0	3.2
FGF21 analogue	71	0	3.3
GLP-1/GCG dual RA	59	0	4.3
FGF19 analogue	49.8	0	5
PPAR agonist	39.3	0	5.9
d-(R)-Pioglitazone	28.7	0	6.7
FXR agonist	17.1	0	7.6
Placebo	12.5	0	8



Supplementary Table 5.16. Liver stiffness measurement assessed by vibration controlled transient elastography

Treatment	SUCRA	PrBest	Mean Rank
FGF21 analogue	89.8	57.5	1.5
GLP-1/GIP dual RA	86.6	39.7	1.7
GLP-1 RA	46.8	0.6	3.7
FXR agonist	35.7	2.2	4.2
PPAR agonist	34.8	0	4.3
Placebo	6.3	0	5.7

